Lock Up and Voting Agreement (March 31st, 2009)
IN WITNESS WHEREOF, Parent and each of the Stockholders have caused this Voting Agreement to be duly executed as of the day and year first above written.
Contract (June 8th, 2006)
Exhibit 10.5 Phase III Medical, Inc. 330 South Service Road Suite 120 Melville, New York 11747 Attention: Dr. Joseph Zuckerman, Director June 2, 2006 Dear Joe: This letter is being written to confirm certain understandings relating to my employment with Phase III Medical, Inc. (the "Company"). I understand that in connection with a proposed financing (the "Financing") by DC Associates LLC ("Duncan") as lead investor, Duncan is requiring certain executives of the Company to accept a 25% reduction in their salary until certain milestones in the Company's development are achieved. My revised salary under this executive compensation plan (the "Executive Compensation Plan") and the milestones that result in its upward adjustment are set forth in the attachment to this letter which also appears as an exhibit to the Securities Purchase Agreement for the Financing. In consideration for agreeing to be bound by the Executive Compensation Plan, the Company is granting to me an option un
Contract (March 31st, 2005)
EXHIBIT 10.8 Zuckerman Board of Directors Agreement Exhibit 10.8 PHASE III MEDICAL, INC. 330 South Service Road Suite 120 Melville, New York 11747 631.574.4955 January 20, 2004 Joseph D. Zuckerman, M.D. Professor and Chairman NYU-Hospital for Joint Diseases Department of Orthopaedic Surgery 301 East 17th Street New York, New York 10003 Dear Dr. Zuckerman: We are pleased to extend to you an invitation to become a Director of the Phase III Medical, Inc. (the "Company"). As you know, the Company is a public company that, among other items, is entering the medical sector by acquiring or participating in one or more biotechnology and/or medical companies or technologies, owning one or more drugs or medical devices that may or may not yet be available to the general public and/or acquiring rights to one or more of such drugs or medical devices or the royalty streams therefrom. We are reque